MEDIA ADVISORY - Testosterone therapy class action commenced in Canada
22 Jul, 2014, 15:10 ET
TORONTO, July 22, 2014 /CNW/ - The law firm Siskinds LLP has launched a class action regarding the testosterone therapy drug Delatestryl.
Testosterone therapy (or testosterone replacement therapy) is often used to treat low testosterone levels, also known as "low T" or hypogonadism, in men. Prescription testosterone injections, gels, patches, buccal systems and pills are all forms of testosterone therapy.
The Statement of Claim alleges that the defendants failed to adequately warn patients and physicians that use of testosterone therapy increases the risk of serious cardiovascular side effects, including heart attack, stroke, deep vein thrombosis, pulmonary embolism and death.
Linda Visser, a lawyer with Siskinds LLP, states: "In commencing the class action, Siskinds is seeking recovery for Canadians who took testosterone therapy and were not warned of the increased risk of suffering serious cardiovascular side effects, including heart attack, stroke, deep vein thrombosis, pulmonary embolism and death." She further states: "As a matter of safety, patients and their health care providers need to be informed of the risks associated with using a particular pharmaceutical product."
Canadians who have experienced adverse events after using any form of testosterone therapy are encouraged to visit www.classaction.ca/testosterone, email [email protected] or call 1-800-461-6166 ext. 2406 for English enquiries or ext. 2409 for French enquiries.
About Siskinds LLP
Siskinds LLP is a full-service law firm with offices in Toronto and London, and affiliate offices in Montreal and Quebec City. Siskinds LLP has a large class actions practice.
SOURCE: Siskinds LLP
For further information: Linda Visser or Jill S. McCartney, Siskinds LLP, 100 Lombard Street, Suite 302, Toronto, ON M5C 1M3, Tel: (416) 362-8334, Email: [email protected]; please reference docket number 3704CP/14
Share this article